Former Medivation CEO is Named Axovant CEO After Pfizer Buys MedivationBy
Axovant Sciences, a Bermuda-based clinical-stage biopharmaceutical company focused on treating dementia, has named David Hung, MD, as chief executive officer (CEO), effective April 7, 2017. Dr. Hung, who also joined Axovant’s board of directors, succeeds founding CEO, Vivek Ramaswamy. Mr. Ramaswamy will continue to serve on Axovant’s board of directors and will lead parent company and majority owner, Roivant Sciences, as its full-time CEO.
Dr. Hung brings more than 20 years of leadership and management experience in the life-sciences industry. He was the founder, president, and CEO of Medivation, a San Francisco-based biopharmaceutical company, until Medivation’s acquisition by Pfizer for approximately $14 billion in September 2016.
During his tenure as CEO, Medivation achieved FDA approval for Xtandi (enzalutamide) for treating metastatic castration-resistant prostate cancer. Prior to his founding and leadership experience with Medivation, Dr. Hung served as president and CEO at ProDuct Health from 1999 until its acquisition by Cytyc Corporation in 2001 and was vice president of new projects as well as was responsible for lead discovery and development at Chiron Corporation.
In addition to Dr. Hung’s appointment, Axovant has also named former Medivation executive, Marion McCourt, as president and chief operating officer (COO). Ms. McCourt served as COO of Medivation from February 2016 through to its acquisition by Pfizer. Prior to joining Medivation, Ms. McCourt served as vice president, commercial operations, US, at Amgen. Prior to that, she also served as vice president and general manager of the Bone Health & Primary Care Business Unit at Amgen. Before joining Amgen, Ms. McCourt served in numerous positions of increasing responsibility at AstraZeneca, including as COO of AstraZeneca US, where she was responsible for all US commercial functions, medical affairs, business development, finance, human resources, legal, operations, and corporate affairs.
Source: Axovant Sciences